» Articles » PMID: 32964372

Considering the Societal Perspective in Economic Evaluations: a Systematic Review in the Case of Depression

Overview
Journal Health Econ Rev
Publisher Biomed Central
Specialty Public Health
Date 2020 Sep 23
PMID 32964372
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Depressive disorders are associated with a high burden of disease. However, due to the burden posed by the disease on not only the sufferers, but also on their relatives, there is an ongoing debate about which costs to include and, hence, which perspective should be applied. Therefore, the aim of this paper was to examine whether the change between healthcare payer and societal perspective leads to different conclusions of cost-utility analyses in the case of depression.

Methods: A systematic literature search was conducted to identify economic evaluations of interventions in depression, launched on Medline and the Cost-Effectiveness Registry of the Tufts University using a ten-year time horizon (2008-2018). In a two-stepped screening process, cost-utility studies were selected by means of specified inclusion and exclusion criteria. Subsequently, relevant findings was extracted and, if not fully stated, calculated by the authors of this work.

Results: Overall, 53 articles with 92 complete economic evaluations, reporting costs from healthcare payer/provider and societal perspective, were identified. More precisely, 22 estimations (24%) changed their results regarding the cost-effectiveness quadrant when the societal perspective was included. Furthermore, 5% of the ICURs resulted in cost-effectiveness regarding the chosen threshold (2% of them became dominant) when societal costs were included. However, another four estimations (4%) showed the opposite result: these interventions were no longer cost-effective after the inclusion of societal costs.

Conclusions: Summarising the disparities in results and applied methods, the results show that societal costs might alter the conclusions in cost-utility analyses. Hence, the relevance of the perspectives chosen should be taken into account when carrying out an economic evaluation. This systematic review demonstrates that the results of economic evaluations can be affected by different methods available for estimating non-healthcare costs.

Citing Articles

No prediction without prevention: A global qualitative study of attitudes toward using a prediction tool for risk of developing depression during adolescence.

Kohrt B, Wahid S, Ottman K, Burgess A, Viduani A, Martini T Glob Ment Health (Camb). 2025; 11():e129.

PMID: 39777002 PMC: 11704374. DOI: 10.1017/gmh.2024.136.


Value is Gendered: The Need for Sex and Gender Considerations in Health Economic Evaluations.

Mchenga M, Vijayasingham L, RamPrakash R, Remme M Appl Health Econ Health Policy. 2024; 23(2):171-181.

PMID: 39666245 PMC: 11811431. DOI: 10.1007/s40258-024-00930-z.


Economic Evaluation of Cervical Cancer Screening by HPV DNA, VIA, and Pap smear Methods in Indonesia.

Hafidz F, Icanervilia A, Rizal M, Listiani P, Setyaningsih H, Sasanti M Asian Pac J Cancer Prev. 2024; 25(9):3015-3022.

PMID: 39342578 PMC: 11700344. DOI: 10.31557/APJCP.2024.25.9.3015.


Adoption of a Societal Perspective in Economic Evaluations of Musculoskeletal Disorders: A Conceptual Paper.

Fatoye F, Gebrye T, Nherera L, Trueman P J Mark Access Health Policy. 2024; 12(3):216-223.

PMID: 39193540 PMC: 11348208. DOI: 10.3390/jmahp12030018.


On spillovers in economic evaluations: definition, mapping review and research agenda.

Mendoza-Jimenez M, van Exel J, Brouwer W Eur J Health Econ. 2024; 25(7):1239-1260.

PMID: 38261132 PMC: 11377364. DOI: 10.1007/s10198-023-01658-8.


References
1.
Groessl E, Tally S, Hillery N, Maciel A, Garces J . Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder. J Manag Care Spec Pharm. 2018; 24(8):726-734. PMC: 10397625. DOI: 10.18553/jmcp.2018.24.8.726. View

2.
Antonanzas F, Rodriguez-Ibeas R, Juarez C, Hutter F, Lorente R, Pinillos M . Transferability indices for health economic evaluations: methods and applications. Health Econ. 2008; 18(6):629-43. DOI: 10.1002/hec.1397. View

3.
Romero-Sanchiz P, Nogueira-Arjona R, Garcia-Ruiz A, Luciano J, Campayo J, Gili M . Economic evaluation of a guided and unguided internet-based CBT intervention for major depression: Results from a multi-center, three-armed randomized controlled trial conducted in primary care. PLoS One. 2017; 12(2):e0172741. PMC: 5328395. DOI: 10.1371/journal.pone.0172741. View

4.
Choi S, Brignone M, Cho S, Jeon H, Jung R, Campbell R . Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea. Expert Rev Pharmacoecon Outcomes Res. 2015; 16(5):629-638. DOI: 10.1586/14737167.2016.1128830. View

5.
Vataire A, Aballea S, Antonanzas F, Roijen L, Lam R, McCrone P . Core discrete event simulation model for the evaluation of health care technologies in major depressive disorder. Value Health. 2014; 17(2):183-95. DOI: 10.1016/j.jval.2013.11.012. View